Correction: A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis

Liu, Zeming; Zeng, Wen; Chen, Tianwen; Guo, Yawen; Zhang, Chao; Liu, Chunping; Huang, Tao

doi:10.18632/oncotarget.24998

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our analyses, patients with cPTC were more likely to carry the BRAFV600E mutation ( I 2 = 0.0%, P = .964, RR = 1.24, 95% CI 1.18‐1.31), similar to the findings of Xing et al, 36 and cPTC was associated with a poorer prognosis compared with the other PTC subtypes 37 . Some studies reported that the TERTp mutation is more prevalent in patients with tall‐cell PTC, which is one of the most aggressive subtypes 34,38 . However, our studies did not provide sufficient information about the correlations between mutation status and the PTC histological variant, but we still call for more further explorations on their potential correlations so that clinicians could combine the results comprehensively to make a precise risk stratifications and decide the personalized treatment.…”

Section: Discussionsupporting

confidence: 87%

The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta‐analysis

Chen

Shi

et al. 2020

Clinical Endocrinology

View full text Add to dashboard Cite

BRAFV600E mutation is highly prevalent in patients with papillary thyroid carcinoma (PTC), and TERT promoter (TERTp) mutation is strongly associated with cancer‐related mortality. However, predictive power of the two mutations remains inconclusive. We aimed to verify the prognostic effects of both mutations to assess the value of mutation detection for risk stratification in terms of PTC prognosis and tumour invasion, to guide PTC diagnosis and treatment. We conducted a literature search in the MEDLINE (PubMed), EMBASE, Web of Science and CENTRAL (Cochrane library) databases, from inception to February 2020. Basic characteristics, prognoses and clinicopathological features were collected from the included studies for further analysis. Twelve studies involving 4184 PTC patients were enrolled in our analysis. In total, 2412 (57.6%) of the patients carried either BRAFV600E or TERTp mutation, and 290 (6.9%) patients had both mutations. TERTp mutation was more common in patients with BRAFV600E mutation (RR = 1.75 [95% CI 1.44‐2.13]). Patients with both mutations had a worse prognosis compared with those with a single mutation (vs BRAFV600E only: RR = 5.34 [4.20‐6.78] vs TERTp only: RR = 2.12 [1.41‐3.19]). TERTp mutation alone independently increased the risk of a poor prognosis (RR = 2.90 [1.93‐4.35]) in terms of mortality (RR = 15.09 [7.75‐29.37]), disease persistence (RR = 4.00 [2.03‐7.90]), recurrence (RR = 4.34 [4.20‐6.78]), lymph node metastasis (RR = 1.57 [1.24‐1.99]) and distant metastasis (RR = 2.94 [1.13‐7.65]). We found that PTC patients with BRAFV600E mutation were more likely to have TERTp mutation. TERTp mutation was an independent predictive factor for poor prognosis of PTC patients, but the predictive value of BRAFV600E mutation remains inconclusive. Patients with both mutations have remarkably higher risks of adverse outcomes compared with those with a single mutation. PTC patients could benefit from mutation detection for aiding risk stratification (BRAF + TERT+ > BRAF − TERT+ > BRAF + TERT−).

show abstract

Section: Discussionsupporting

confidence: 87%

The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta‐analysis

Chen

Shi

et al. 2020

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Recent studies found that the tall cell subtype, columnar cell subtype, and hobnail subtype are associated with more aggressive disease [ 12 , 26 ]. The tall cell subtype was found to be linked to ETE, extensive locoregional and distant metastasis, and a worse prognosis.…”

Section: Discussionmentioning

confidence: 99%

The Impact of BRAF V600E Mutation Allele Frequency on the Histopathological Characteristics of Thyroid Cancer

Abdulhaleem,

Bandargal,

Pusztaszeri

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: A BRAF V600E mutation in papillary thyroid cancer (PTC) has been shown to be associated with aggressive behavior. Nevertheless, not all BRAF V600E PTCs behave aggressively. Allele frequency (AF) is the number of mutated molecules divided by the total number of wild-type molecules at a specific location in the genome. The relationship between BRAF V600E AF and the histopathological features of thyroid malignancies is not well understood. We hypothesized that the BRAF V600E AF will correlate directly with aggressive histopathological behavior. The aim of this study was to examine this relationship. Methods: A retrospective chart review was performed for patients treated for BRAF V600E thyroid malignancies from 2019 to 2022 at McGill University tertiary care hospitals (n = 317). Patients with BRAF V600E-positive malignancies that included information on AF were included (n = 44). The correlation between AF and tumor histopathological features was analyzed. Results: Out of the 44 nodules with a BRAF V600E mutation, those with aggressive features of PTC had a mean AF of 25.8%, which was significantly higher than the non-aggressive group with a mean AF of 10.25% (p = 0.020). Additionally, there was a statistically significant difference in mean AF between patients with a positive sentinel LN (29%) and those with a negative sentinel LN (17.8%) (p = 0.021). Classical PTC was present in 29.5% (13/44) of nodules, with a mean AF of 15.6%. The tall cell subtype was found in 64% (28/44) of nodules, with a mean AF of 23%. Solid and hobnail subtypes were less common in this study, and there was no statistically significant relationship between AF and histopathological subtypes (p = 0.107). Nodules smaller than 1cm had a mean AF of 13.3%, while nodules ranging from 1 2cm had a mean AF of 20.6%, and those larger than 2cm had a mean AF of 27.7%. However, no statistical difference was observed between AF and nodule size (p = 0.160). Conclusion: In this study, BRAF V600E mutations in conjunction with AF help to determine whether thyroid malignancies will display aggressive behavior. This pre-operative finding can help thyroid specialists to determine the extent of thyroidectomy and whether lymph node dissection is required.

show abstract

“…The American Thyroid Association (ATA) guidelines classify the tall cell variant (TCV), columnar cell variant (CCV), hobnail variant (HV), diffuse sclerosing variant (DSV), and solid variant (SV) as being of intermediate risk [ 3 ]. Compared with cPTC, TCV is associated with higher extrathyroidal extension, more extensive locoregional or distant metastasis, and poorer prognosis and is also an independent factor for an aggressive disease course [ 4 , 5 , 6 , 7 , 8 ]. CCV and HV have a high risk of distant metastasis and cancer-specific mortality [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…CCV and HV have a high risk of distant metastasis and cancer-specific mortality [ 9 , 10 , 11 ]. These three subtypes/variants are often accompanied by BRAF (V600E) mutation [ 6 , 12 ]. Compared with cPTC, DSV is more prevalent in young female patients with radiation exposure, is more often diagnosed at an advanced stage, and has a higher risk of recurrence and distant metastasis.…”

Section: Introductionmentioning

confidence: 99%

Predictive Factors Indicative of Hemithyroidectomy and Close Follow-Up versus Bilateral Total Thyroidectomy for Aggressive Variants of Papillary Thyroid Cancer

Lee

Moon

Kang

et al. 2022

Cancers

View full text Add to dashboard Cite

The diagnostic and treatment rates of early thyroid cancer have been increasing, including those of aggressive variants of papillary thyroid cancer (AVPTC). This study aimed to analyze the need for completion total thyroidectomy after lobectomy for clinically low-to-intermediate-risk AVPTC. Overall, 249 patients who underwent hemithyroidectomy (HT, n = 46) or bilateral total thyroidectomy (BTT, n = 203) for AVPTC between November 2005 and December 2019 at our single institution were examined. The average follow-up period was 14.9 years, with a recurrence rate of 4.3% and 10.8% in the HT and BTT groups, respectively. Multivariate Cox analysis revealed that palpable tumor on the neck during evaluation (HR, 2.7; 95% CI, 1.1–6.4; p = 0.025), clinical N1b (HR, 8.3; 95% CI, 1.1–63.4; p = 0.041), tumor size (cm) (HR, 1.3; 95% CI, 1.0–1.7; p = 0.036), gross extrathyroidal extension (HR, 3.1; 95% CI, 1.4–7.0; p = 0.007), and pathologic T3b (HR, 3.4; 95% CI, 1.0–11.4; p = 0.045) or T4a (HR, 6.0; 95% CI, 1.9–18.8; p = 0.002) were associated with an increased risk of recurrence. Incidentalomas identified during diagnosis had a significantly lower risk of recurrence (HR, 0.4; 95% CI, 0.2–0.9; p = 0.033). Close follow-up may be performed without completion total thyroidectomy for AVPTC found incidentally after HT.

show abstract

Correction: A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis

Cited by 4 publications

References 0 publications

The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta‐analysis

The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta‐analysis

The Impact of BRAF V600E Mutation Allele Frequency on the Histopathological Characteristics of Thyroid Cancer

Predictive Factors Indicative of Hemithyroidectomy and Close Follow-Up versus Bilateral Total Thyroidectomy for Aggressive Variants of Papillary Thyroid Cancer

Contact Info

Product

Resources

About